<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="829">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <nctid>NCT00192634</nctid>
  <trial_identification>
    <studytitle>A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study</studytitle>
    <scientifictitle>A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ACTRN012605000505606</secondaryid>
    <secondaryid>STEAL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Emtricitabine 200mg - Tenofovir 300mg
Treatment: drugs - Abacavir 600mg - Lamivudine 300mg

Active Comparator: 1 - Abacavir 600mg/Lamivudine 300mg

Active Comparator: 2 - Tenofovir 300mg/emtricitabine 200mg


Treatment: drugs: Emtricitabine 200mg - Tenofovir 300mg
1 tablet once daily for 96 weeks

Treatment: drugs: Abacavir 600mg - Lamivudine 300mg
1 tablet once daily for 96 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>virological failure defined by HIV RNA&gt;400copies/mL plasma on 2 consecutive occasions ³4 wks apart(Roche Amplicor v1.5, LLD 50 copies/mL)</outcome>
      <timepoint>Week 48</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>plasma HIV RNA&lt;50copies/mL; time to virological failure (VF); virological resistance in those with VF; all SAEs; use of concomitant meds for toxicity; adherence; QoL; CD4+lymphocyte count; full blood count; biochemistry; lipid parameters</outcome>
      <timepoint>Week 48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>glycaemic parameters; DEXA parameters; resolution of AEs; progression to AIDS; death; discontinuation of ART.</outcome>
      <timepoint>Week 48 and 96</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  documented HIV infection

          -  age at least 18 years

          -  stable (= to 12 weeks) ART including at least two NRTIs, currently well tolerated,
             with no plan to change any other component of the ART regimen at or after baseline

          -  HIV RNA &lt; 50 copies/mL plasma for the preceding 12 weeks

          -  GFR = 70 mL/min/1.73m2 (estimated by the abbreviated MDRD equation23 estimated GFR =
             186 x ([SCR/88.4]-1.154) x age-0.203 x (0.742 if female) x (1.210 if African-American)

          -  provision of written, informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  HLA-B*5701 positive at screening OR evidence of previous ABC hypersensitivity OR
             clinical failure in participants taking abacavir for at least 30 days

          -  current therapy comprising triple NRTI therapy alone

          -  current use of ABC/3TC FDC (Kivexa) or TDF/FTC FDC (Truvada)

          -  history of non-traumatic osteoporotic fracture

          -  prior hypersensitivity or intolerance to ABC, 3TC, TDF or FTC

          -  prior clinical failure to a regimen containing ABC or TDF

          -  prior use of TDF for control of previously active hepatitis B (HBsAg+ or HBV DNA+) in
             patients likely to be resistant to 3TC/FTC

          -  current therapy including unboosted atazanavir

          -  concurrent use of aminoglycosides, IV amphotericin B, cidofovir, cisplatin, foscarnet,
             IV pentamidine, probenecid, adefovir or immunomodulatory agents

          -  clinical evidence of cirrhosis (e.g. smooth liver, no features of portal hypertension)

          -  creatinine clearance &lt; 50 mL/min (estimated by the Cockcroft-Gault equation)18,19

               -  Male: (140 - age in years) x (wt in kg) = CLCr (mL/min) 0.814 x (serum creatinine
                  in µmol/L)

               -  Female:(140 - age in years) x (wt in kg) x 0.85 = CLCr (mL/min) 0.814 x (serum
                  creatinine in µmol/L)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>357</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Holdsworth House General Practice - Byron Bay - Byron Bay</hospital>
    <hospital>Lismore Sexual Health Clinic - Northen Rivers Area Health Service - Lismore</hospital>
    <hospital>John Hunter Hospital - Newcastle</hospital>
    <hospital>407 Doctors - Sydney</hospital>
    <hospital>Albion Street Centre - Sydney</hospital>
    <hospital>Holdsworth House General Practice - Sydney</hospital>
    <hospital>St. Vincent's Hospital - Sydney</hospital>
    <hospital>Taylor Square Private Clinic - Sydney</hospital>
    <hospital>Prince of Wales Hospital - Sydney</hospital>
    <hospital>Clinic 16, Royal North Shore Hospital - Sydney</hospital>
    <hospital>Burwood Road Practice - Sydney</hospital>
    <hospital>Westmead Hospital - Sydney</hospital>
    <hospital>Liverpool Health Service - Sydney</hospital>
    <hospital>QLD Health - AIDS Medical Unit - Brisbane</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <hospital>Gladstone Road Medical Centre - Brisbane</hospital>
    <hospital>Doll's House Clinic - Cairns Base Hospital - Cairns</hospital>
    <hospital>Gold Coast Sexual Health Clinic - Miami</hospital>
    <hospital>Clinic 87, Nambour Hospital - Nambour</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>The Care and Prevention Programme - Adelaide University - Adelaide</hospital>
    <hospital>Flinders Medical Centre - Adelaide</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Carlton Clinic - Melbourne</hospital>
    <hospital>Melbourne Sexual Health Centre - Melbourne</hospital>
    <hospital>Prahran Market Clinic - Melbourne</hospital>
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <hospital>The Centre Clinic - Melbourne</hospital>
    <hospital>Royal Melbourne Hospital - Melbourne</hospital>
    <hospital>Fremantle Hospital - Fremantle</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2481 - Byron Bay</postcode>
    <postcode>2480 - Lismore</postcode>
    <postcode>2304 - Newcastle</postcode>
    <postcode>2010 - Sydney</postcode>
    <postcode>2031 - Sydney</postcode>
    <postcode>2065 - Sydney</postcode>
    <postcode>2134 - Sydney</postcode>
    <postcode>2145 - Sydney</postcode>
    <postcode>2170 - Sydney</postcode>
    <postcode>4002 - Brisbane</postcode>
    <postcode>4029 - Brisbane</postcode>
    <postcode>4101 - Brisbane</postcode>
    <postcode>4870 - Cairns</postcode>
    <postcode>4220 - Miami</postcode>
    <postcode>4560 - Nambour</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5042 - Adelaide</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3053 - Melbourne</postcode>
    <postcode>3141 - Melbourne</postcode>
    <postcode>3168 - Melbourne</postcode>
    <postcode>3182 - Melbourne</postcode>
    <postcode>3403 - Melbourne</postcode>
    <postcode>6160 - Fremantle</postcode>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Kirby Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Combination antiretroviral therapy for the treatment of HIV has a high pill burden. Two
      dual-tablets, abacavir-lamivudine and tenofovir-emtricitabine, are now licensed in the United
      States and will be available in Australia in December 2005. Data available suggest that the
      potency of these tablets are similar in controlling replication of the HIV virus, but not
      have not been directly compared in regard to clinically significant toxicities. We therefore
      aim to compare the overall safety and efficacy of the two dual-tablets over a 2 year period
      in HIV infected adults. We hypothesise that the two dual-NRTI treatments will be similar in
      efficacy and safety.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00192634</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Carr, MD FRACP FRCPA</name>
      <address>Kirby Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>